迎來業務里程碑,知行科技新獲某頭部自主品牌5款車型的定點函
據知行科技官方消息,近日知行科技新再次迎來業務里程碑,獲得某頭部自主品牌5款車型的定點函 ,包括主流量產乘用車和商用車等多款車型。
知行科技將爲其提供輔助駕駛域控和前視一體機等多種解決方案,充分滿足不同車型定位和海內外市場的差異化需求。此次新定點項目中,包含基於地平線徵程6M(簡稱'J6M')芯片的ADAS解決方案,將實現包括輕量化城區功能在內的高階行泊能力,這也是知行科技再次獲得J6M平臺定點項目。
值得一提的是,知行科技6月曾宣佈獲得9款商用車平臺化定點。從6月初截止現在,知行科技在30天內累計獲得14款車型定點。市場分析人士指出,2025年輔助駕駛技術已逐漸進入大規模商業化階段,產業進入快速發展期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.